AWARDDEFINITIVE CONTRACTSmall business
Definitive contract W81XWH19C018160 DEGREES PHARMACEUTICALS, INC.
Overview
Award facts
- Net obligations
- $5.47M
- $5,473,597of $5.97M potential value
- Period of performance
- Sep 1, 2019 to Aug 31, 2022
- Ended
- Modifications
- 8
- Latest action Jul 1, 2025
- Contract type
- Definitive contract
- PIID W81XWH19C0181
Description of requirement
BRAND NAME ARAKODA MALARIA PROPHYLACTIC DRUG TAFENOQUINE
Dates and value
- Award date
- Signed on Sep 1, 2019
- Potential end of performance
- Aug 30, 2022
- Current value
- $5,473,597Base and exercised options
- Potential value (if all options are exercised)
- $5,971,272
Obligations by fiscal year of action
- FY2025: -$28,966 (de-obligation)
- FY2021: $1,138,200
- FY2020: $2,226,863
- FY2019: $2,137,500
Total across 4 fiscal years: $5,473,597
Net de-obligation in that fiscal year (obligations withdrawn).
The Department of Defense funded and awarded this contract. DoD contract actions are withheld at the source for about 90 days after signature, so actions signed after Aug 17, 2026 are not yet public.
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Jul 1, 2025. View on USAspending · Recipient on SAM.gov
Recipient
LocationWASHINGTON, DC
UEIWKN5DNLTVF95
CAGE code71D06
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent company60 DEGREES PHARMACEUTICALS INC.
Business types and certifications
For-profit organizationCorporation (not tax-exempt)Manufacturer of goods
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Defense
- Defense Health Agency
- ARMY MED RES ACQ ACTIVITY
- Funded by
- Department of Defense
- Department Of The Army
- W4QF USA MMDA
- Funded from
- N/a; Field is optional prior to fy21Program activities021-2040Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Washington, District Of Columbia County, District Of Columbia 20036-5417
- Congressional district (place of performance)
- DC-98As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- 6505DRUGS AND BIOLOGICALS (product)
Competition
- Extent competed
- Not competedC
- Reason not competed
- Only one source-other (FAR 6.302-1 other)ONE
- Solicitation procedures
- Only one sourceSSS
- Set-aside
- No set-aside used
- Contract pricing
- Firm fixed priceJ
- Offers received
- 1
Solicitation and notices
- Solicitation ID
- W81XWH19R0061(as reported)
- Solicitation date
- Jul 17, 2019
Contract details
- Subcontracting plan
- Plan not requiredB
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/servicesA
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 1, 2019Base obligation at award: $2,137,500
- Latest action
- Jul 1, 2025 — Supplemental agreement (within scope)Modification P00008; obligation change -$28,966
- Latest substantive action
- Jul 1, 2025 — Supplemental agreement (within scope)Modification P00008; obligation change -$28,966
- Actions by type
- Base award1
- Supplemental agreement (within scope)4
- Option exercised3
- Novation (contract transferred)1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
- A-76 (FAIR Act) action
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- -$28,966
- Latest action: change in base and all options
- -$28,966
Socio-economic and policy
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Meets requirementsA
- Clinger-Cohen Act planning (IT)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- IndiaIND
- Place of manufacture
- Mfg outside U.S. - domestic nonavailabilityJ
- Sea transportation
- UnknownU
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- IT commercial item category
- Not IT products or servicesZ
- DoD claimant program
- All others not identifiable to any other procurement programC9E
- Awarding agency code
- 9700
- Awarding sub-tier code
- 97DH
- Contracting office code
- HT9425
- Transactions recorded under this award key
- 9
Funding
- Funding agency code
- 9700
- Funding sub-tier code
- 2100
- Funding office code
- W806YH
- Treasury accounts
- 021-2020/2021-2040-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- N: Emergency P.L. 116-136
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression
- COVID-19 supplemental obligations
- $1,158,113